Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Fenfluramine is a synthetic pharmaceutical agent primarily classified as a serotonin-releasing and reuptake inhibitor, historically utilized for its appetite-suppressing properties. Its molecular formula is C12H17N, corresponding to a molecular weight of approximately 175.27 g/mol. The substance is uniquely identified by the CAS registry number 693-40-5. Originally developed in the late 1950s, fenfluramine gained widespread popularity as an anti-obesity medication, often prescribed in combination with phentermine under the brand name Fen-Phen. However, due to severe adverse cardiac events linked to valvular heart disease and pulmonary hypertension, it was withdrawn from the global market in 1997 following extensive regulatory scrutiny.
In recent years, the therapeutic profile of fenfluramine has undergone a significant transformation. Clinical research has uncovered its potent efficacy in treating rare and severe forms of epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. Consequently, it has been re-approved by major health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), under the brand name Fintepla. Unlike its historical use for weight loss, the modern application focuses on reducing seizure frequency in pediatric and adult patients who have not responded adequately to other antiepileptic drugs.
The mechanism of action involves increasing synaptic serotonin levels, which modulates neuronal excitability and helps stabilize electrical activity in the brain associated with seizures. Despite this renewed indication, strict monitoring remains essential. Patients must undergo regular echocardiograms to screen for potential cardiac valvulopathy, a known risk factor even at therapeutic doses for epilepsy. Furthermore, fenfluramine is available only through specialized restricted distribution programs to ensure safe administration and patient oversight. While no longer a weight-loss drug, fenfluramine represents a critical advancement in neurology, offering hope to individuals suffering from debilitating seizure disorders that were previously difficult to manage. Its journey from a banned diet pill to a life-saving neurological treatment highlights the dynamic nature of pharmacological discovery and safety evaluation.